EIKN.US Eikon Therapeutics, Inc. Common Stock
- Market cap
- USD 324M
- P/E
- -
- P/B
- 0.70x
- ROE
- -89.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EIKN.US undervalued?
Graham numberThe Graham number of Eikon Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eikon Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Eikon Therapeutics, Inc. Common Stock yet.
Eikon Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to addre…
Full company profileEikon Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eikon Therapeutics, Inc. Common Stock annual financial statements
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | -24.2M | -20.2M |
| Operating Income | -266M | -260M | -339M | -362M |
| EBITDA | -224M | -218M | -299M | -342M |
| Net Income | -242M | -244M | -324M | -343M |
| EPS | -4.48 | -4.52 | -5.99 | -6.34 |
| Balance Sheet | ||||
| Total Assets | 526M | 491M | 595M | 706M |
| Total Liabilities | 867M | 1.06B | 1.47B | 322M |
| Shareholders' Equity | -341M | -572M | -879M | 384M |
| Cash & Short-term Investments | 113M | 129M | 336M | 462M |
| Total Debt | - | - | 257M | 250M |
| Cash Flow | ||||
| Operating Cash Flow | -191M | -135M | -189M | -299M |
| Capital Expenditure | 28.5M | 84.8M | 46.7M | 1.24M |
| Free Cash Flow | -219M | -220M | -235M | -300M |
| Ratios | ||||
| ROE | - | - | - | -89.3% |
| ROA | -46.0% | -49.6% | -54.5% | -48.6% |
| Debt to Equity | - | - | - | 0.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eikon Therapeutics, Inc. Common Stock dividends
Eikon Therapeutics, Inc. Common Stock has not paid dividends in the last 3 fiscal years.
Who owns Eikon Therapeutics, Inc. Common Stock
- Insiders 17.38%
- Institutions 72.49%
- Public & others 10.13%
- Shares outstanding 54.2M
- Free float 34.8M
Top funds holding EIKN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BGF World Healthscience A2 | 1.52M | 2.81% | 0.00% | Jul 2026 |
| Fidelity Contrafund | 1.27M | 2.35% | -0.16% | Sep 2026 |
| Fidelity Select Biotechnology | 1.17M | 2.16% | +1.58% | Aug 2026 |
| American Funds SMALLCAP World A | 1.14M | 2.11% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 849K | 1.57% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 788K | 1.45% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 739K | 1.37% | -11.03% | Sep 2026 |
| Fidelity Growth Company Fund | 731K | 1.35% | +15.41% | Aug 2026 |
| BlackRock Health Sciences Opps Inv A | 722K | 1.33% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 660K | 1.22% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 434K | 0.80% | -1.75% | Sep 2026 |
| Fidelity Contrafund K6 | 265K | 0.49% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 248K | 0.46% | +4.31% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 223K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 207K | 0.38% | +15.64% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 205K | 0.38% | -0.38% | Oct 2026 |
| Fidelity Series Growth Company | 187K | 0.35% | +15.29% | Aug 2026 |
| Vanguard Russell 2000 ETF | 187K | 0.34% | +49.39% | Sep 2026 |
| AB Small Cap Core Z | 172K | 0.32% | +144.40% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 153K | 0.28% | +0.23% | Oct 2026 |
Top institutions holding EIKN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 4.99M | 9.22% | +30.16% | Jun 2026 |
| BlackRock Inc | 4.28M | 7.90% | +28.98% | Jun 2026 |
| Foresite Capital Management IV, LLC | 1.94M | 3.59% | 0.00% | Jun 2026 |
| Merck & Co Inc | 1.67M | 3.08% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.60M | 2.95% | +30.49% | Jun 2026 |
| Foresite Capital Management V, LLC | 1.32M | 2.44% | 0.00% | Jun 2026 |
| Capital World Investors | 1.18M | 2.17% | +2.82% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.01M | 1.86% | +2.99% | Jun 2026 |
| Vanguard Capital Management, LLC | 923K | 1.70% | -4.82% | Jun 2026 |
| EcoR1 Capital, LLC | 733K | 1.35% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 642K | 1.19% | -37.20% | Jun 2026 |
| Geode Capital Management, LLC | 557K | 1.03% | +103.32% | Jun 2026 |
| Baker Bros Advisors LP | 556K | 1.03% | 0.00% | Jun 2026 |
| SOROS CAPITAL MANAGEMENT LLC | 485K | 0.89% | 0.00% | Jun 2026 |
| StepStone Group LLC | 395K | 0.73% | 0.00% | Jun 2026 |
| Canada Pension Plan Investment Board | 379K | 0.70% | 0.00% | Jun 2026 |
| State Street Corp | 354K | 0.65% | +781.93% | Jun 2026 |
| Franklin Templeton Inc | 350K | 0.65% | 0.00% | Jun 2026 |
| General Catalyst Group Management, LLC | 305K | 0.56% | 0.00% | Jun 2026 |
| UBS Group AG | 264K | 0.49% | +165.50% | Jun 2026 |
Eikon Therapeutics, Inc. Common Stock company profile
- Company name
- Eikon Therapeutics, Inc. Common Stock
- Ticker
- EIKN.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 384
- Fiscal year end
- December
- Address
- 230 Harriet Tubman Way, Millbrae, CA, United States, 94030
- Phone
- 341 777 0566
- Website
- eikontx.com
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Eikon Therapeutics, Inc. Common Stock management
10- Dr. Roger M. Perlmutter M.D., Ph.D.Chairman, President & CEO · born 1952
- Mr. Michael A. KlobucharChief Operating Officer · born 1976
- Dr. Roy D. Baynes FACP, M.D., Ph.D.Executive VP & Chief Medical Officer · born 1955
- Dr. Robert Tjian Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1949
- Dr. Eric Betzig Ph.D.Co-Founder & Member of Scientific Advisory Board
- Dr. Alfred Lloyd Bowie Jr., Ph.D.Treasurer & CFO · born 1982
- Mr. Russ BermanChief Technology Officer
- Dr. Ching-Pin Chang M.D., Ph.D.Executive VP & Chief Scientific Officer
- Mr. Benjamin Bruno ThornerSecretary, General Counsel & Chief Business Officer · born 1971
- Ms. Barbara Howes M.B.A.Chief People Officer · born 1965